OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
May 17, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the discovery and development of novel molecules...
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
May 16, 2022 18:12 ET
|
OKYO Pharma LTD
LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel...
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 27, 2022 02:00 ET
|
OKYO Pharma LTD
OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice LONDON, April 27, 2022 (GLOBE...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States
March 07, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) ("OKYO" or the "Company"), a biotechnology company focused on the discovery and development of novel...
OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain
February 23, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity
February 21, 2022 12:00 ET
|
OKYO Pharma LTD
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease
February 15, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings
February 01, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited- PDMR Dealing
January 27, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited - Interim results for the six months to 30 September 2021
January 26, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO) a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye...